Remission of a negative Her2/Neu overexpressive metastatic ovarian cancer patient by the single agent of trastuzumab as salvage therapy [2]

Gynecologic Oncology

Volumn 101, Issue 1, 2006, Pages 184-185

  Tai, Cheng Jeng ^a   Lo, Horng Yuan ^a   Hsu, Chung Huei ^a   Tai, Chen Jei ^a   Liu, Wei Min ^a  

^a TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TOPOTECAN; TRASTUZUMAB;

AGED; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; CANCER REGRESSION; CANCER STAGING; CASE REPORT; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LETTER; METASTASIS; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALVAGE THERAPY; VAGINA BLEEDING;

AGED; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; SALVAGE THERAPY;

EID: 33644521604     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.11.043     Document Type: Letter

References (2)

1. M.A. Bookman, K.M. Darcy, D. Clarke-Pearson, R.A. Boothby, and I.R. Horowitz Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group J. Clin. Oncol. 21 2003 283 290
2. A. Aigner, H. Juhl, C. Malerczyk, A. Tkybusch, C.C. Benz, and F. Czubayko Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation Oncogene 20 2001 2101 2111